Search Result

Results for "

lung injury model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Annexin A (2) Antibiotic (1) Apoptosis (9) Autophagy (4) Bacterial (4) Caspase (1) CCR (1) Complement System (1) COX (2) CXCR (1) Dipeptidyl Peptidase (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (1) ERK (1) Ferroptosis (3) FGFR (1) HSV (1) IKK (2) Interleukin Related (4) IRAK (2) Isotope-Labeled Compounds (1) Keap1-Nrf2 (2) Liposome (1) MAPKAPK2 (MK2) (1) Mitophagy (2) mTOR (1) MyD88 (1) NF-κB (8) NO Synthase (5) NOD-like Receptor (NLR) (3) Opioid Receptor (2) p38 MAPK (4) Phosphodiesterase (PDE) (2) PI3K (1) Pim (3) PINK1/Parkin (2) PKD (3) Pyroptosis (1) Thymidylate Synthase (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (33) Metabolic Disease (3) Neurological Disease (3)

By Targets:

Akt (2)

Annexin A (2)

Antibiotic (1)

Apoptosis (9)

Autophagy (4)

Bacterial (4)

Caspase (1)

CCR (1)

Complement System (1)

COX (2)

CXCR (1)

Dipeptidyl Peptidase (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (1)

ERK (1)

Ferroptosis (3)

FGFR (1)

HSV (1)

IKK (2)

Interleukin Related (4)

IRAK (2)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (2)

Liposome (1)

MAPKAPK2 (MK2) (1)

Mitophagy (2)

mTOR (1)

MyD88 (1)

NF-κB (8)

NO Synthase (5)

NOD-like Receptor (NLR) (3)

Opioid Receptor (2)

p38 MAPK (4)

Phosphodiesterase (PDE) (2)

PI3K (1)

Pim (3)

PINK1/Parkin (2)

PKD (3)

Pyroptosis (1)

Thymidylate Synthase (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

VEGFR (1)

Virus Protease (1)

By Research Areas:

Cancer (12)

Cardiovascular Disease (1)

Infection (5)

Inflammation/Immunology (33)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103363

SB-328437 1 Publications Verification	CCR Thymidylate Synthase	Inflammation/Immunology Cancer
SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC₅₀ of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .

HY-P1098

Ac2-26 4 Publications Verification	Annexin A NF-κB	Inflammation/Immunology
Ac2-26 is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-172135

PDE4-IN-26	p38 MAPK Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-26 (Compound A5) is an orally active and highly selective PDE4 inhibitor. PDE4-IN-26 has anti-inflammatory activity and can inhibit the phosphorylation of p38 MAPK. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 can improve pulmonary inflammation, injury and fibrosis, promote sputum secretion and relieve cough in mice. PDE4-IN-26 can be used for the research of lung injury-related diseases .

HY-168009

NLRP3-IN-45	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-45 (D6) is an inhibitor of NLRP3 inflammasome activation, inhibiting the activity of IL-1β (IC₅₀=41.79 nM). NLRP3-IN-45 exerts its effects without affecting the initial stage of NLRP3 inflammasome activation. NLRP3-IN-45 specifically inhibits the activation of NLRP3 inflammasome in the LPS-induced acute lung injury (ALI) mouse model .

HY-167891

GPD-1116	Phosphodiesterase (PDE) Apoptosis	Inflammation/Immunology
GPD-1116 is an orally active Phosphodiesterase (PDE) 4 and PDE1 inhibitor. GPD-1116 can reduce smoke-induced apoptosis of lung cells. GPD-1116 is effective in several disease models in animals, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension .

HY-158315

NZ-97	Dipeptidyl Peptidase	Inflammation/Immunology
NZ-97 is an inhibitor for dipeptidyl peptidase 4 (DPP4) with an IC₅₀ of 18 nM. NZ-97 exhibits a low initial plasma exposure with C_max of 0.13 µM, which is eliminated in 8 h. NZ-97 ameliorates damage in the Lipopolysaccharides (HY-D1056)-induced lung injury and Bleomycin (HY-108345)-induced lung fibrosis in mice model .

HY-169420

IL-6-IN-1	Interleukin Related	Inflammation/Immunology
IL-6-IN-1 (Compound 22) inhibits the release of IL-6 with an IC₅₀ of 1.065 μM. IL-6-IN-1 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced acute lung injury in mouse model .

HY-172102

NLRP3-IN-68	NO Synthase NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-68 (Compound 2d) is a 1,3,4-oxadiazole derivative. NLRP3-IN-68 has strong anti-inflammatory and antioxidant activities, which can inhibit inflammatory cytokines secretion, iNOS expression and NLRP3 inflammasome activation. NLRP3-IN-68 can be used in the research of anti-inflammatory drugs .

HY-114366

BC-1485	CXCR	Others
BC-1485 is a small molecule inhibitor of Fibrosis-inducing E3 ligase 1 (FIEL1). BC-1485 protects PIAS4 from ubiquitin-mediated degradation. BC-1485 decreases α-SMA, BAL and CXCL1. BC-1485 ameliorates fibrotic lung injury in murine models .

HY-165603

Si5-N14	Liposome VEGFR FGFR	Cardiovascular Disease Inflammation/Immunology Cancer
Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .

HY-P1098A

Ac2-26 TFA 4 Publications Verification	Annexin A NF-κB	Inflammation/Immunology
Ac2-26 TFA is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-128423AS

Tylvalosin-d9 Acetylisovaleryltylosin-d₉	Isotope-Labeled Compounds Apoptosis Antibiotic NF-κB Bacterial	Others
Tylvalosin-d₉ (Acetylisovaleryltylo?sin-d₉) is the deuterium labeled Tylvalosin (HY-128423A) . Tylvalosin is a third-generation macrolide, with anti-inflammatory property. Tylvalosin decreases the levels of IL-8, IL-6, IL-1β, PGE2, TNF-α and NO, and reduces the inflammatory cells recruitment and activation in mouse acute lung injury model .

HY-P99583

Suvratoxumab MEDI4893	Bacterial	Infection Inflammation/Immunology
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .

HY-15698A

CRT0066101 dihydrochloride 2 Publications Verification	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 dihydrochloride is a potent and orally active PKD inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 dihydrochloride is also a potent PIM2 inhibitor with an IC₅₀ of ~135.7 nM. CRT0066101 dihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .

HY-15698

CRT0066101 2 Publications Verification	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 is a potent and orally active PKD inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 is also a potent PIM2 inhibitor with an IC₅₀ of ~135.7 nM. CRT0066101 exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .

HY-P1098B

Ac2-26 ammonium 4 Publications Verification	IKK	Inflammation/Immunology
Ac2-26 ammonium is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 ammonium induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ammonium ameliorates lung ischemia-reperfusion injury. Ac2-26 ammonium also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-12119B

GW274150 dihydrochloride	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation .

HY-12119

GW274150 2 Publications Verification	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation .

HY-12119A

GW274150 phosphate 2 Publications Verification	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .

HY-15698B

CRT0066101 trihydrochloride	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active PKD inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2 with an IC₅₀ of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .

HY-172406

MAPK-IN-4	p38 MAPK Interleukin Related IRAK	Inflammation/Immunology
MAPK-IN-4 (Compound c1) is an orally active anti-inflammatory agent. MAPK-IN-4 can inhibit the expression and release of pro-inflammatory cytokines IL-6 and TNF-α induced by LPS (HY-D1056). MAPK-IN-4 can bind to IRAK4 and exert its anti-inflammatory effect by inhibiting the MAPK pathway .

HY-N0591

Dehydrocostus Lactone 1 Publications Verification (-)-Dehydrocostus lactone; Epiligulyl oxide	Bacterial Apoptosis p38 MAPK NF-κB MAPKAPK2 (MK2) Akt NO Synthase Interleukin Related Caspase	Infection Inflammation/Immunology Cancer
Dehydrocostus Lactone is a natural sesquiterpene that can be isolated from Saussurea lappa. Dehydrocostus Lactone has multiple activities such as anti-inflammatory, antibacterial, anti-tumor, and immunomodulatory effects. Dehydrocostus Lactone has an MIC of 2 µg/mL against Mycobacterium tuberculosis. Dehydrocostus Lactone can also inhibit the killing activity of cytotoxic T lymphocytes and induce apoptosis in tumor cells .

HY-149992

MyD88-IN-1	MyD88	Inflammation/Immunology Cancer
MyD88-IN-1 (Compound c17) is an orally active MyD88 inhibitor. MyD88-IN-1 inhibits the interaction of TLR4 and MyD88 and suppressed the NF-κB pathway. MyD88-IN-1 can be used in research of cancer and inflammatory .

HY-N0632

Esculentoside A 2 Publications Verification	COX NF-κB	Inflammation/Immunology
Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta . Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models , has selective inhibitory activity towards cyclooxygenase-2 (COX-2) . Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways .

HY-160876

BC-1901S	Keap1-Nrf2 E1/E2/E3 Enzyme	Inflammation/Immunology
BC-1901S is a proteasome-independent NRF2 activator and stabilizer. BC-1901S binds to DCAF1 (E3 ligase subunit) and disrupts NRF2/DCAF1 interaction, and activates NRF2 by inhibiting NRF2 ubiquitination in a KEAP1-independent manner. BC-1901S shows anti-inflammatory effect in a murine model of LPS-induced acute lung injury .

HY-168709

Nrf2 activator 18	Keap1-Nrf2	Inflammation/Immunology
Nrf2 activator 18 (Compound 11a) is an orally active activator for Keap1/Nrf2/HO-1 signaling pathway, that promotes the Nrf2 nuclear translocation, and enhances the antioxidant efficacy. Nrf2 activator 18 inhibits the release of IL-6 with an IC₅₀ of 4.816 μM. Nrf2 activator 18 exhibits anti-inflammatory efficacy in mouse PM2.5-induced lung injury model .

HY-162641

AF-45	IRAK NF-κB p38 MAPK TNF Receptor	Inflammation/Immunology
AF-45 inhibits IRAK4 and IRAK1, with IC₅₀s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and TNF-α in macrophages, with IC₅₀s of 0.53-1.54 μM and 0.6-2.75 μM. AF-45 is also an inhibitor for NF-κB/MAPK signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models .

HY-N6871

Abietic acid	Bacterial IKK Ferroptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .

HY-N0632R

Esculentoside A (Standard)	COX NF-κB	Inflammation/Immunology
Esculentoside A (Standard) is the analytical standard of Esculentoside A. This product is intended for research and analytical applications. Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta . Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models , has selective inhibitory activity towards cyclooxygenase-2 (COX-2) . Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways .

HY-N9481

Lipoteichoic acid	Complement System Autophagy mTOR Akt PI3K ERK Interleukin Related	Infection Metabolic Disease Inflammation/Immunology Cancer
Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin .

HY-N0469R

L-Lysine (Standard)	Endogenous Metabolite Virus Protease HSV	Infection Metabolic Disease Inflammation/Immunology
L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC₅₀ & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium . L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .

HY-168207

TH023	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
TH023 is an inhibitor for the TLR4 signaling pathway, that targets especially the formation of TLR4 homodimer. TH023 inhibits secreted embryonic alkaline phosphatase in cell HEK-Blue hTLR4 with an IC₅₀ of 0.354 μM, and inhibits the NO expression in RAW264.7 with an IC₅₀ of 1.61μM. TH023 also inhibits the activation of NF-κB, reduces the nuclear translocation of NF-κB p65. TH023 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced mouse acute sepsis model, and ameliorates the mouse lung injury .

HY-N0164R

Matrine (Standard)	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis	Inflammation/Immunology Cancer
Matrine (Standard) is the analytical standard of Matrine. This product is intended for research and analytical applications. Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-N0164

Matrine Maximum Cited Publications 14 Publications Verification Matridin-15-one; Vegard; α-Matrine	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis	Inflammation/Immunology Cancer
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-N3005

Britannin 1 Publications Verification	Apoptosis Autophagy NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology Cancer
Britannin is an NLRP3 inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics .

Cat. No.	Product Name	Target	Research Area